661 related articles for article (PubMed ID: 16999455)
1. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
2. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
3. Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.
Penner J; Wells JL; Borrie MJ; Woolmore-Goodwin SM; Bartha R
Dement Geriatr Cogn Disord; 2015; 39(1-2):68-80. PubMed ID: 25358336
[TBL] [Abstract][Full Text] [Related]
4. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
5. Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study.
Schott JM; Frost C; MacManus DG; Ibrahim F; Waldman AD; Fox NC
Brain; 2010 Nov; 133(11):3315-22. PubMed ID: 20739347
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine for vascular cognitive impairment.
Birks J; McGuinness B; Craig D
Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
[TBL] [Abstract][Full Text] [Related]
7. 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease.
Henigsberg N; Kalember P; Hrabać P; Rados M; Bajs M; Rados M; Kovavić Z; Loncar M; Madzar T
Coll Antropol; 2011 Jan; 35 Suppl 1():159-62. PubMed ID: 21648328
[TBL] [Abstract][Full Text] [Related]
8. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
[TBL] [Abstract][Full Text] [Related]
9. The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.
Modrego PJ
Curr Med Chem; 2006; 13(28):3417-24. PubMed ID: 17168714
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
[TBL] [Abstract][Full Text] [Related]
11. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
12. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
[TBL] [Abstract][Full Text] [Related]
13. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
15. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment.
Fayed N; Dávila J; Oliveros A; Medrano J; Castillo J
Neurol Res; 2010 Mar; 32(2):157-65. PubMed ID: 20158954
[TBL] [Abstract][Full Text] [Related]
16. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Waldman AD; Rai GS
Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326
[TBL] [Abstract][Full Text] [Related]
17. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Huang W; Alexander GE; Chang L; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
Neurology; 2001 Aug; 57(4):626-32. PubMed ID: 11524470
[TBL] [Abstract][Full Text] [Related]
18. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
[TBL] [Abstract][Full Text] [Related]
19. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
20. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
